Evaluate the Continued Safety and Effectiveness of the XIENCE PRIME EECSS in a Cohort of Real-world Patients Receiving the XIENCE PRIME EECSS During Commercial Use.

Trial Profile

Evaluate the Continued Safety and Effectiveness of the XIENCE PRIME EECSS in a Cohort of Real-world Patients Receiving the XIENCE PRIME EECSS During Commercial Use.

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 03 Feb 2016

At a glance

  • Drugs Everolimus (Primary)
  • Indications Coronary artery disease; Coronary artery restenosis; Myocardial infarction
  • Focus Therapeutic Use
  • Acronyms XP China SAS
  • Sponsors Abbott Vascular
  • Most Recent Events

    • 31 Jul 2015 Planned primary completion date changed from 1 Jul 2014 to 1 Sep 2019 as reported by ClinicalTrials.gov
    • 12 Jan 2015 Planned End Date changed from 1 Jul 2019 to 1 Sep 2019 as reported by ClinicalTrials.gov record.
    • 06 Aug 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top